Candel Therapeutics, Inc. (CADL) has 18 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 4 sales totalling $3.7M. Most recent filing: Sept. 11, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 11, 2026 filed Sept. 10, 2026 | Tak Paul Peter Chief Executive Officer | −$1,750,953 | 530,245 | −58% | Yes | |
|
|
||||||
| Sept. 10, 2026 filed Sept. 8, 2026 | Zimmermann Martine Director | $0 | 64,000 | 0% | No | |
|
|
||||||
| Aug. 19, 2026 filed Aug. 17, 2026 | Tyagarajan Seshu Chief Technology Officer | −$84,000 | 7,000 | −8% | Yes | |
|
|
||||||
| July 8, 2026 filed July 6, 2026 | Sims Mark E. Chief Commercial Officer | $0 | 285,000 | 0% | No | |
|
|
||||||
| July 1, 2026 filed June 29, 2026 | Barone Francesca Chief Scientific Officer | −$235,769 | 23,447 | −23% | Yes | |
|
|
||||||
Showing the 5 most recent of 18 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free